Sorry, you need to enable JavaScript to visit this website.

Results with TECVAYLI® (teclistamab-cqyv)

Yellow pointer iconResults with TECVAYLI®

TECVAYLI® was studied in 110 adults, 78% of whom had already been on at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

People icon

More than half of adults saw results with TECVAYLI® in the clinical trial

62%

62% of people who took TECVAYLI® responded.

1 month calendar icon

Median time to first response with TECVAYLI® was 1.2 months (response times ranged from 0.2 months to 5.5 months).

 

Once you and your doctor have decided that TECVAYLI® is right for you, Janssen has resources to help support your treatment journey.

Personalized one-on-one support

Starting and staying on track with a new medication can feel overwhelming. A Janssen Compass® Care Navigator is here to help with free personalized one-on-one support over the phone throughout your treatment journey.

You will talk to the same Care Navigator on every phone call. They will help you in 3 key areas:

  • Explore options that may help you pay for your medication
  • Learn more about your cancer and Janssen medication
  • Find resources for your practical and emotional needs while coping with cancer

Janssen Compass® is limited to education about your Janssen therapy, its administration, and/or your disease. It is intended to supplement your understanding of your therapy and is not intended to provide medical advice, replace a treatment plan from your doctor or nurse, or serve as a reason for you to start or stay on this medication.